Tags

Type your tag names separated by a space and hit enter

Critical appraisal of antileukotriene use in asthma management.
Curr Opin Pulm Med. 2007 Jan; 13(1):24-30.CO

Abstract

PURPOSE OF REVIEW

Recognition of the importance of leukotrienes in the pathogenesis of asthma has led to the development of leukotriene modifiers, the first new class of drugs for asthma treatment to become available since the introduction of inhaled corticosteroids. Nevertheless, despite their widespread use in clinical practice, the role of leukotriene modifiers in the management of asthma remains controversial. In the present article the clinical applications of this class of drugs have been critically reviewed based on recent evidence.

RECENT FINDINGS

In an effort to try and establish the proper place of antileukotrienes in the management of asthma, important systematic reviews have been carried out over these recent years in three critical areas: antileukotrienes as second choice first line agents after inhaled corticosteroids; antileukotrienes as add-on therapy to inhaled corticosteroids; add-on antileukotrienes versus long acting beta-agonists to patients not controlled by inhaled corticosteroids. In addition, novel and useful clinical targets for this class of drugs have been recently explored and include: patients with severe asthma; aspirin-intolerant asthma; asthmatic patients with allergic rhinitis.

SUMMARY

Use of antileukotrienes is not recommended as first-line monotherapy in patients with asthma, except those who have aspirin intolerant asthma. Patients with concomitant allergic rhinitis may be a good target population for therapy with antileukotrienes. Addition of leukotriene modifiers to inhaled corticosteroids produces only a modest improvement in the clinical response, and is not greater to that of add-on long acting beta-agonists. The exact role of antileukotrienes in asthma management guidelines still continues to evolve.

Authors+Show Affiliations

Department of Internal and Specialist Medicine, Ascoli-Tomaselli Hospitals, University of Catania, Italy. polosa@unict.it

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

17133121

Citation

Polosa, Riccardo. "Critical Appraisal of Antileukotriene Use in Asthma Management." Current Opinion in Pulmonary Medicine, vol. 13, no. 1, 2007, pp. 24-30.
Polosa R. Critical appraisal of antileukotriene use in asthma management. Curr Opin Pulm Med. 2007;13(1):24-30.
Polosa, R. (2007). Critical appraisal of antileukotriene use in asthma management. Current Opinion in Pulmonary Medicine, 13(1), 24-30.
Polosa R. Critical Appraisal of Antileukotriene Use in Asthma Management. Curr Opin Pulm Med. 2007;13(1):24-30. PubMed PMID: 17133121.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Critical appraisal of antileukotriene use in asthma management. A1 - Polosa,Riccardo, PY - 2006/11/30/pubmed PY - 2007/2/16/medline PY - 2006/11/30/entrez SP - 24 EP - 30 JF - Current opinion in pulmonary medicine JO - Curr Opin Pulm Med VL - 13 IS - 1 N2 - PURPOSE OF REVIEW: Recognition of the importance of leukotrienes in the pathogenesis of asthma has led to the development of leukotriene modifiers, the first new class of drugs for asthma treatment to become available since the introduction of inhaled corticosteroids. Nevertheless, despite their widespread use in clinical practice, the role of leukotriene modifiers in the management of asthma remains controversial. In the present article the clinical applications of this class of drugs have been critically reviewed based on recent evidence. RECENT FINDINGS: In an effort to try and establish the proper place of antileukotrienes in the management of asthma, important systematic reviews have been carried out over these recent years in three critical areas: antileukotrienes as second choice first line agents after inhaled corticosteroids; antileukotrienes as add-on therapy to inhaled corticosteroids; add-on antileukotrienes versus long acting beta-agonists to patients not controlled by inhaled corticosteroids. In addition, novel and useful clinical targets for this class of drugs have been recently explored and include: patients with severe asthma; aspirin-intolerant asthma; asthmatic patients with allergic rhinitis. SUMMARY: Use of antileukotrienes is not recommended as first-line monotherapy in patients with asthma, except those who have aspirin intolerant asthma. Patients with concomitant allergic rhinitis may be a good target population for therapy with antileukotrienes. Addition of leukotriene modifiers to inhaled corticosteroids produces only a modest improvement in the clinical response, and is not greater to that of add-on long acting beta-agonists. The exact role of antileukotrienes in asthma management guidelines still continues to evolve. SN - 1070-5287 UR - https://www.unboundmedicine.com/medline/citation/17133121/Critical_appraisal_of_antileukotriene_use_in_asthma_management_ L2 - https://doi.org/10.1097/MCP.0b013e3280107bda DB - PRIME DP - Unbound Medicine ER -